{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fcannacast-il.simplecast.com%2Fepisodes%2Fcovid-19-a-revolutionary-treatment-approach-llC75cU3","width":444,"version":"1.0","type":"rich","title":" COVID-19 - A revolutionary treatment approach!","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/87cff0ab-cad9-4e7b-9e34-7615b173b9f8/113e9576-0e1c-4cb6-8b2c-feb664054838/cncst_1.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/67b9d807-694d-42a9-a6da-d0450b74349c\" height=\"200\" width=\"100%\" title=\" COVID-19 - A revolutionary treatment approach!\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode, Iris Bincovich, CEO of Innocan Pharma shares Innocan’s collaboration with Tel Aviv University to develop a novel, revolutionary approach to treat COVID-19 by using CBD loaded Exosomes. In addition to treating COVID-19, the new drug will target additional central nervous system indications. The goal is to be ready in 2021 to conduct a licensing agreement with a large pharma company.\nAdditionally, Iris shared that Innocan will be launching their new line of CBD topicals, produced in Portugal and the US, during Q2 of this year, including a line of “relief and go” pain-relief topicals as well as a line of cosmetic products.\nInterested in being a distributor? Contact:  irisb@innocanpharma.com\n"}